Keywords: USA, Medicare, Insurance, Onglyza, Bristol-Myers Squibb, AstraZeneca

Onglyza gets 44% coverage of US commercial health plans but less than 1%of Medicare for type 2 diabetes

Article | 14 October 2009

Recently-approved for marketing in the treatment of type 2 diabetes in the USA, Bristol-Myers Squibb/AstraZeneca's Onglyza (saxagliptin) is covered by 44% ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in

Related Companies

Astra Zeneca

AstraZeneca

Bristol-Myers Squibb

Go to company listing